Cardiff Oncology, Inc.
CRDF$205M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaSAN DIEGO32 employees
Drugs in Pipeline
6
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 4, 2026
6wMarket Overview
Stock performance and key metrics
CRDF News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
FOLFIRI
Metastatic Colorectal Cancer
Onvansertib
Colorectal Cancer
Cytarabine
Acute Myeloid Leukemia
Abiraterone
Metastatic Castration-Resistant Prostate Cancer
Nanoliposomal irinotecan
Pancreatic Ductal Adenocarcinoma
FOLFOX
Metastatic Colorectal Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FOLFIRI | Phase 2 | Metastatic Colorectal Cancer | - | - |
Onvansertib | Phase 2 | Colorectal Cancer | - | - |
Cytarabine | Phase 2 | Acute Myeloid Leukemia | - | - |
Abiraterone | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | - | - |
Nanoliposomal irinotecan | Phase 2 | Pancreatic Ductal Adenocarcinoma | - | - |
FOLFOX | Phase 2 | Metastatic Colorectal Cancer | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply